Table 2.
Distribution of concentrations and WHO-TEQs of PCDD/Fs and PCBs in adolescent boys from Chapaevsk, Russia
| Congener | Average DL | # of samples above DLa | Concentrations | WHO-TEF | WHO-TEQ (pg TEQ/g lipid) | ||||
| Percentiles | Percentiles | ||||||||
| 25-th | Median | 75-th | 25-th | Median | 75-th | ||||
| PCDDs (pg/g lipid) | |||||||||
| 2,3,7,8-TCDD | 4.1 | 2/29 | 0.00 | 0.00 | 0.00 | 1.000 | 0.00 | 0.00 | 0.00 |
| 1,2,3,7,8-PeCDD | 4.8 | 12/30 | 0.00 | 0.00 | 8.30 | 1.000 | 0.00 | 0.00 | 8.30 |
| 1,2,3,6,7,8-HxCDD | 7.1 | 1/30 | 0.00 | 0.00 | 0.00 | 0.100 | 0.00 | 0.00 | 0.00 |
| 1,2,3,7,8,9-HxCDD | 6.9 | 3/30 | 0.00 | 0.00 | 0.00 | 0.100 | 0.00 | 0.00 | 0.00 |
| 1,2,3,4,6,7,8-HpCDD | 14.6 | 15/30 | 9.40 | 14.9 | 25.1 | 0.010 | 0.09 | 0.15 | 0.25 |
| 1,2,3,4,6,7,9-HpCDD | 9.0 | 0/30 | 0.00 | 0.20 | 1.70 | 0.0000 | 0.00 | 0.00 | 0.00 |
| OCDD | 73.1 | 15/29 | 32.9 | 75.0 | 100 | 0.0001 | 0.00 | 0.01 | 0.01 |
| PCDFs (pg/g lipid) | |||||||||
| 2,3,7,8-TCDF | 3.9 | 0/30 | 0.00 | 0.00 | 0.00 | 0.1000 | 0.00 | 0.00 | 0.00 |
| 1,2,3,7,8-PeCDF | 4.7 | 1/30 | 0.00 | 0.00 | 0.00 | 0.050 | 0.00 | 0.00 | 0.00 |
| 2,3,4,7,8-PeCDF | 4.5 | 29/30 | 8.50 | 12.6 | 17.4 | 0.500 | 4.25 | 6.30 | 8.75 |
| 1,2,3,4,7,8-HxCDF | 4.2 | 27/30 | 5.50 | 9.15 | 20.1 | 0.100 | 0.55 | 0.92 | 2.01 |
| 1,2,3,6,7,8-HxCDF | 4.5 | 21/30 | 0.00 | 5.70 | 8.70 | 0.100 | 0.00 | 0.57 | 0.87 |
| 1,2,3,7,8,9-HxCDF | 4.2 | 0/30 | 0.00 | 0.00 | 0.00 | 0.100 | 0.00 | 0.00 | 0.00 |
| 2,3,4,6,7,8-HxCDF | 4.5 | 1/30 | 0.00 | 0.00 | 1.80 | 0.100 | 0.00 | 0.00 | 0.18 |
| 1,2,3,4,6,7,8-HpCDF | 16.8 | 0/30 | 3.00 | 5.30 | 10.5 | 0.010 | 0.03 | 0.05 | 0.11 |
| 1,2,3,4,7,8,9-HpCDF | 6.0 | 0/30 | 0.00 | 0.00 | 0.00 | 0.010 | 0.00 | 0.00 | 0.00 |
| Coplanar PCBs (pg/g lipid) | |||||||||
| 3,4,4',5-TCB 81 | 11.0 | 2/30 | 0.00 | 0.00 | 1.60 | 0.0001 | 0.00 | 0.00 | 0.00 |
| 3,3',4,4',5-PeCB 126 | 25.3 | 30/30 | 43.3 | 68.4 | 116 | 0.1000 | 4.33 | 6.84 | 11.6 |
| 3,3',4,4',5,5'-HxCB 169 | 7.7 | 28/30 | 27.3 | 44.2 | 54.3 | 0.0100 | 0.27 | 0.44 | 0.54 |
| Mono-ortho PCBs (ng/g lipid) | |||||||||
| 2,3,3',4,4'-PeCB (105) | 11.0 | 9/27 | 5.6 | 7.1 | 11.8 | 0.0001 | 0.56 | 0.71 | 1.18 |
| 2,3',4,4',5-PeCB (118) | 11.0 | 27/27 | 20.7 | 28.0 | 51.6 | 0.0001 | 2.07 | 2.80 | 5.16 |
| 2,3,3',4,4',5-HxCB (156) | 11.0 | 10/27 | 7.5 | 9.1 | 15.9 | 0.0005 | 3.75 | 4.55 | 7.95 |
| 2,3,3',4,4',5'-HxCB (157) | 11.0 | 0/27 | 2.3 | 2.6 | 4.3 | 0.0005 | 1.15 | 1.30 | 2.15 |
| 2,3',4,4',5,5'-HxCB (167) | 11.0 | 0/27 | 1.6 | 2.0 | 3.7 | 0.00001 | 0.02 | 0.03 | 0.04 |
| 2,3,3',4,4',5,5'-HpCB (189) | 10.9 | 0/25 | 0.4 | 0.6 | 0.8 | 0.0001 | 0.04 | 0.06 | 0.08 |
| Total PCDDs (pg/g lipid) | 40.9 | 95.8 | 144 | 0.10 | 0.29 | 9.14 | |||
| Total PCDFs (pg/g lipid) | 20.4 | 33.9 | 61.8 | 5.27 | 7.98 | 12.3 | |||
| Total coplanar PCBs (pg/g lipid) | 77.6 | 120 | 157 | 4.51 | 7.39 | 11.9 | |||
| Total PCDD/F/coplanar PCBs (pg/g lipid) | 154 | 273 | 397 | 12.1 | 17.1 | 38.1 | |||
| Total Mono-ortho PCBs (ng/g lipid) | 39.2 | 47.7 | 78.4 | 7.16 | 8.80 | 15.5 | |||
| Total TEQs | 30.9 | 46.8 | |||||||
Abbreviations: DL, detection limit.
Note: 1,2,3,4,7,8-HxCDD, OCDF, and 3,3',4,4'-TCB 77 were not reported in the present study due to interferences in method blanks.
aResults for some samples could not be reported because one or more of the analytical QA/QC criteria were not met. Therefore, the denominator may be less than 30.